Dermatofibroma

1. Clinical Overview

Summary

Dermatofibroma (benign fibrous histiocytoma) is one of the most common benign skin nodules encountered in clinical practice, representing a reactive fibrous proliferation within the dermis rather than a true neoplasm. [1] The lesion typically arises following minor cutaneous trauma such as arthropod bites, folliculitis, or superficial injuries, triggering a localized proliferation of fibroblasts and histiocytes. [2,3] These firm, hyperpigmented nodules show a strong predilection for the lower extremities of young to middle-aged women and are characterized by the pathognomonic Fitzpatrick's Sign (dimple sign). [4]

While dermatofibromas are entirely benign and require no treatment in the majority of cases, they serve as important clinical entities for several reasons: they are frequent causes of patient anxiety requiring reassurance; they must be distinguished from melanoma and dermatofibrosarcoma protuberans; and their management involves careful patient counseling regarding the cosmetic outcomes of intervention versus observation. [5,6]

Key Clinical Facts

Nature and Classification

• Reactive Process: Not a true neoplasm but a localized fibroproliferative response to injury
• Histological Variant: Part of the spectrum of fibrous and fibrohistiocytic tumors
• Alternative Names: Benign fibrous histiocytoma, sclerosing hemangioma (misnomer), histiocytoma cutis
• Cellular Origin: Derived from dermal dendrocytes (Factor XIIIa-positive cells) [7]

Distribution and Demographics

• Location: 80% occur on lower extremities, particularly anterior tibial region [8]
• Gender: Female predominance (3-4:1 ratio)
• Age: Peak incidence 20-45 years; uncommon in children
• Multiplicity: Solitary in 80-90% of cases; multiple lesions warrant investigation

Clinical Characteristics

• Texture: Firm, button-like consistency—"feels deeper than it looks"
• Size: Typically 3-10mm diameter; lesions > 2cm raise suspicion for DFSP
• Color: Variable from pink to brown, often with darker periphery
• Evolution: Slow growth to stable size over months, then persist indefinitely
• Symptoms: Usually asymptomatic; occasionally pruritic or tender

Clinical Pearls

The Fitzpatrick's Sign (Dimple Sign): This clinical finding is virtually pathognomonic for dermatofibroma. When lateral pressure is applied by pinching the skin on either side of the lesion, the nodule appears to retract or dimple inward. This occurs because the proliferating fibrous tissue tethers the overlying epidermis to the deeper dermis and subcutaneous tissue. In contrast, melanocytic nevi, lipomas, and cysts will bulge upward or remain neutral with lateral compression. [4] This simple bedside test has high specificity and can provide immediate diagnostic reassurance.

The "Razor Bump" Phenomenon: Women frequently present with dermatofibromas on the legs complaining of recurrent bleeding after shaving. This occurs because the firm, slightly elevated nodule catches the razor blade during leg shaving. This is a mechanical issue, not a sign of malignancy, but it represents a legitimate quality-of-life concern that may justify removal in selected patients.

Surgical Counseling: The most common patient request is for removal, often for cosmetic reasons or irritation. However, excision is generally discouraged unless there is diagnostic uncertainty. The counseling message should be: "I can remove this, but you will be trading a small brown bump for a permanent linear scar." On the lower legs, scars heal poorly, tend to stretch, and often become more conspicuous than the original lesion. Cryotherapy may reduce pigmentation but rarely eliminates the palpable component.

The Multiple Eruption Red Flag: While solitary dermatofibromas are benign reactive lesions, the sudden appearance of multiple eruptive dermatofibromas (> 15 lesions) has been associated with systemic immunosuppression including systemic lupus erythematosus, HIV/AIDS, hematological malignancies, and immunosuppressive therapy. [9,10] This warrants appropriate screening and investigation.

---

2. Epidemiology

Prevalence and Incidence

Dermatofibromas are among the most common benign skin lesions presenting to primary care and dermatology clinics, accounting for approximately 3% of all dermatology referrals and up to 10% of excised skin lesions. [11] Population-based studies suggest a prevalence of 1-2% in adults, though many cases go unreported as they are often asymptomatic and may not prompt medical consultation. [12]

Demographic Factors

Age Distribution

• Peak incidence: 20-45 years
• Uncommon before age 15
• Can occur in older adults but less frequently
• Rare in prepubertal children (when present, consider trauma history)

Sex Distribution

• Female-to-male ratio: 3-4:1 [8]
• The female predominance is thought to relate to:
  • Greater awareness of cosmetic concerns
  • Higher exposure to leg shaving trauma
  • Possible hormonal influences (not definitively proven)

Anatomical Distribution

• Lower extremities: 80% (especially anterior shin and thigh) [8]
• Upper extremities: 10-15%
• Trunk: 5-10%
• Face, hands, feet: Rare (less than 5%)
• The predilection for lower legs correlates with sites of minor trauma and insect bites

Racial and Ethnic Considerations

Dermatofibromas occur across all racial and ethnic groups, though clinical recognition may be more challenging in darker skin types due to the variable pigmentation. In individuals with Fitzpatrick skin types IV-VI, the lesions may appear darker brown, black, or violaceous, sometimes raising concern for melanoma. Dermoscopy is particularly valuable in these populations. [13]

Etiological Associations

Trauma and Injury The most widely accepted etiological theory proposes that dermatofibromas represent a reactive fibrous response to localized cutaneous injury. [2,3] Evidence supporting this includes:

• Patient recall of preceding insect bites, scratches, or puncture wounds in 10-30% of cases
• Higher incidence on trauma-prone anatomical sites (shins)
• Histological features consistent with organized wound healing
• Experimental models showing similar proliferation after controlled dermal injury

Immunological States

• Eruptive dermatofibromas (multiple lesions appearing rapidly) have been reported in association with: [9,10]
  • Systemic lupus erythematosus (SLE)
  • HIV infection and AIDS
  • Immunosuppressive therapy (corticosteroids, biologics)
  • Hematological malignancies (leukemia, lymphoma)
  • Solid organ transplantation
• The mechanism is unclear but may involve dysregulated fibroblast proliferation or altered cytokine profiles

Genetic Factors Unlike true neoplasms, dermatofibromas do not show consistent chromosomal abnormalities or hereditary patterns. Occasional familial clustering has been reported but is likely coincidental or related to shared environmental exposures.

---

3. Pathophysiology

Cellular and Molecular Mechanisms

Histogenesis Dermatofibromas represent a clonal or oligoclonal proliferation of dermal dendrocytes—specialized fibroblastic cells that express Factor XIIIa, a marker of dermal dendritic cells involved in wound healing and tissue remodeling. [7,14] The triggering event (trauma, inflammation) induces localized fibroblast activation and proliferation, which then becomes self-sustaining through autocrine and paracrine signaling.

Cell Types Involved The lesion consists of:

1. Fibroblasts: Spindle-shaped cells producing collagen and extracellular matrix
2. Histiocytes: Macrophage-like cells, often multinucleated
3. Dermal dendrocytes: Factor XIIIa-positive cells forming the primary proliferating population
4. Capillaries: Variable vascular component (formerly called "sclerosing hemangioma")
5. Inflammatory cells: Scattered lymphocytes and plasma cells at periphery

Cytokine and Growth Factor Involvement Studies suggest involvement of:

• Transforming Growth Factor-β (TGF-β): Promotes fibroblast proliferation and matrix deposition
• Platelet-Derived Growth Factor (PDGF): Stimulates fibroblast migration and proliferation
• Interleukins: Modulate inflammatory component
• These factors create a microenvironment favoring sustained fibrous proliferation

Histological Architecture

Gross Histology Under scanning magnification, dermatofibromas show:

• Dermal-based proliferation: Poorly circumscribed, centered in the dermis
• Collagen trapping: Thick collagen bundles at the periphery are "trapped" and compressed by the proliferating cells, creating a characteristic pattern [15]
• Epidermal hyperplasia: The overlying epidermis shows reactive acanthosis, rete ridge elongation, and basal hyperpigmentation
• Extension: May extend into superficial subcutis but remains well-contained

Microscopic Patterns Dermatofibromas exhibit several histological subtypes, all benign: [16]

1. Common (typical): Storiform pattern of spindle cells with collagen trapping
2. Cellular: Increased cellularity, can be confused with DFSP
3. Epithelioid: Round cells mimicking epithelioid sarcoma
4. Aneurysmal: Hemorrhagic spaces resembling vascular lesions
5. Lipidized: Foam cells present, mimicking xanthoma
6. Atypical (pseudosarcomatous): Bizarre nuclei, high mitotic rate—still benign
7. Palisading: Resembles neurofibroma

Recognition of these variants is crucial as some (cellular, atypical) can mimic malignancy histologically despite benign behavior.

Immunohistochemistry Immunostaining helps confirm diagnosis and exclude mimics:

• Positive markers:
  • "Factor XIIIa: Strong diffuse positivity (characteristic) [7]"
  • "Vimentin: Positive (mesenchymal marker)"
  • "CD68: Histiocytic component positive"
• Negative markers:
  • "S100: Negative (excludes melanoma, nerve sheath tumors)"
  • "CD34: Negative in dermatofibroma, positive in DFSP (key distinction) [17]"
  • "Keratin: Negative (excludes carcinoma)"
  • "SMA: Focal or negative (extensive positivity suggests leiomyoma)"

Molecular Genetics

Unlike dermatofibrosarcoma protuberans, which harbors the COL1A1-PDGFB fusion gene due to t(17;22) translocation, dermatofibromas lack consistent genetic abnormalities. This supports their classification as reactive rather than neoplastic lesions. Occasional clonal chromosomal changes have been reported in cellular variants, but these do not confer malignant potential.

---

4. Clinical Presentation

Patient History

Chief Complaint Patients typically present with one of the following concerns:

• "I have a hard bump on my leg that won't go away"
• "I keep cutting this mole when I shave"
• "I'm worried this dark spot is skin cancer"
• "I want this removed for cosmetic reasons"

History of Present Illness

• Duration: Usually present for months to years
• Onset: Often insidious; patient may not recall exact onset
• Preceding trauma: In 10-30%, patient recalls insect bite, scratch, or injury weeks to months before noticing the lesion [2]
• Growth pattern: Initial slow enlargement over weeks to months, then stable
• Symptoms: Most are asymptomatic; some report occasional pruritus, tenderness, or irritation from clothing/shaving

Associated Symptoms

• Pain: Unusual; if present, consider tender variants or external irritation
• Bleeding: Only with external trauma (shaving, scratching)
• Ulceration: Rare; if spontaneous, exclude malignancy

Concerning Features (Red Flags) Any of the following warrant biopsy or specialist referral:

• Rapid growth over days to weeks
• Size > 2cm diameter
• Spontaneous ulceration or bleeding
• Asymmetry or irregular borders
• Change in color, especially variegation
• New-onset pain or neurological symptoms
• Multiple eruptive lesions (> 15) [9,10]

Physical Examination

Inspection

• Size: Measure with calipers; typical range 3-10mm
• Shape: Dome-shaped or flat-topped; well-defined but may blend with surrounding skin
• Color:
  • "Early lesions: Pink, red, or tan"
  • "Mature lesions: Brown, dark brown, grey, or black"
  • "Characteristic finding: Darker periphery with lighter center"
• Surface: Smooth, slightly scaly, or may show fine telangiectasia
• Number: Solitary (80-90%) or multiple

Palpation

• Texture: Firm to hard consistency, "button-like"
• Depth: Feels dermal, not subcutaneous (unlike lipoma)
• Mobility: Mobile over underlying fascia/muscle, but tethered to overlying skin
• Tenderness: Usually non-tender; mild tenderness occasionally

Fitzpatrick's Sign (Dimple Sign) This is the pathognomonic clinical test: [4]

1. Pinch the skin on either side of the lesion between thumb and index finger
2. Apply gentle lateral compression
3. Positive test: Lesion dimples or retracts inward
4. Negative test: Lesion remains flat or protrudes outward

Differential Behavior with Lateral Compression:

Dermoscopic Features

Dermoscopy is highly valuable for confirming the diagnosis and excluding melanoma. [18] Key dermoscopic patterns include:

Classical Pattern (Most Common)

• Central white scar-like patch: Corresponds to dermal fibrosis (70-80% of cases) [18]
• Peripheral delicate pigment network: Fine, ring-like or honeycomb network at edges
• Background erythema: Pink-red background, especially in early lesions
• Total white scar-like area: Central white fibrotic zone without pigment structures

Additional Dermoscopic Findings

• Ring-like globules: Peripheral brown globules forming rings
• Atypical vessels: Dotted vessels, comma vessels (not worrisome in context)
• Shiny white lines: Crystalline structures (polarized dermoscopy)
• Hemorrhage: Hemosiderin deposits in aneurysmal variant

Dermoscopy for Excluding Melanoma Melanoma will show:

• Asymmetry of color and structure
• Atypical pigment network or blue-white veil
• Irregular dots and globules
• Regression structures with peppering
• Dermoscopy has > 95% sensitivity for melanoma when used by trained clinicians [13]

Clinical Variants and Subtypes

Standard Dermatofibroma

• Solitary, 5-10mm, brown, lower leg, young woman
• Classic presentation accounts for 80% of cases

Multiple Dermatofibromas

• 2-15 lesions scattered on limbs/trunk
• Usually benign, same management as solitary
• If > 15 lesions or eruptive onset, investigate for immunosuppression [9,10]

Giant Dermatofibroma

• Size > 2cm diameter
• Requires biopsy to exclude dermatofibrosarcoma protuberans
• Histology usually shows benign features

Atypical/Aneurysmal Dermatofibroma

• Rapid enlargement, darker color, may be painful
• Dermoscopy: blue-black hue, blood lakes
• Histology: hemorrhagic spaces with hemosiderin
• Benign but requires biopsy confirmation

Subcutaneous Dermatofibroma

• Deeper variant, extends into subcutis
• Palpable nodule with minimal surface change
• Requires deeper excision if removed

Eruptive Dermatofibromas

• Sudden appearance of > 15 lesions over weeks to months
• Associated with immunosuppression (SLE, HIV, immunosuppressants) [9,10]
• Requires systemic workup

---

5. Differential Diagnosis

The differential diagnosis of a firm, pigmented dermal papule includes both benign and malignant entities. Clinical history, examination findings (especially Fitzpatrick's sign), and dermoscopy narrow the differential significantly.

Key Differentials

1. Melanoma

• Distinction: Asymmetry, irregular borders, color variegation, diameter > 6mm, evolving
• Fitzpatrick's sign: Negative (protrudes or neutral)
• Dermoscopy: Atypical network, blue-white veil, irregular vessels
• Management: Low threshold for biopsy if any doubt

2. Dermatofibrosarcoma Protuberans (DFSP)

• Distinction: Larger (> 2cm), multi-lobulated, protuberant, slow growth over years
• History: "A mole that kept growing"
• Histology: CD34 positive (dermatofibroma is CD34 negative) [17]
• Management: Wide local excision with 2-4cm margins; high recurrence risk

3. Blue Nevus

• Distinction: Blue-grey color, no dimple sign, deeper dermal location
• Dermoscopy: Homogeneous blue pigmentation, no white scar-like area
• Histology: Melanocytes in deep dermis

4. Dermal Melanocytic Nevus

• Distinction: Softer, dome-shaped, uniform brown color
• Fitzpatrick's sign: Negative (protrudes upward)
• Dermoscopy: Globular pattern, no central white patch

5. Leiomyoma (Cutaneous)

• Distinction: Painful, especially with pressure or cold
• Location: Can occur anywhere; multiple (leiomyomatosis)
• Fitzpatrick's sign: May be positive but exquisitely tender
• Histology: Smooth muscle actin positive

6. Keloid or Hypertrophic Scar

• Distinction: Clear history of preceding trauma/surgery
• Location: Corresponds to prior injury site
• Texture: Rubbery, often extending beyond original wound (keloid)
• Color: Pink to red-brown

7. Neurofibroma

• Distinction: Soft, "button-hole" sign (invaginates with pressure)
• Context: Multiple lesions suggest NF1
• Dermoscopy: Fine lines, bag-like appearance

8. Prurigo Nodularis

• Distinction: Intensely pruritic, excoriated surface
• Location: Extensor surfaces, easily reached by scratching
• History: Chronic scratching behavior

9. Epidermoid Cyst

• Distinction: Central punctum (follicular opening)
• Texture: Fluctuant to firm, mobile
• Fitzpatrick's sign: Negative

10. Basal Cell Carcinoma (Pigmented Variant)

• Distinction: Translucent edges, telangiectasia, slow enlargement
• Dermoscopy: Arborizing vessels, blue-grey ovoid nests
• Management: Biopsy required

---

6. Investigations and Diagnosis

Clinical Diagnosis

In the majority of cases (> 95%), the diagnosis of dermatofibroma is made clinically based on: [1,4]

1. History: Asymptomatic or mildly symptomatic dermal nodule, often with remote trauma
2. Examination: Firm, pigmented nodule with positive Fitzpatrick's sign
3. Dermoscopy: Central white scar-like patch with peripheral pigment network

When Clinical Diagnosis is Sufficient:

• Typical appearance and location (lower leg)
• Positive dimple sign
• Reassuring dermoscopic features
• Size less than 1cm
• No concerning features (rapid growth, ulceration, pain)

In these cases, no further investigation is required. Management proceeds to patient education and observation.

Dermoscopy

Dermoscopy (dermatoscopy, epiluminescence microscopy) is a non-invasive adjunct that significantly improves diagnostic accuracy. [18] It is particularly valuable for:

• Confirming typical features (white scar-like patch)
• Excluding melanoma (ruling out atypical networks, blue-white veil)
• Assessing pigmented lesions in darker skin types
• Providing documentation for follow-up

Dermoscopic Algorithm for Dermatofibroma:

• Central white patch: Present in 70-80% → Highly suggestive
• Peripheral delicate network: Ring-like pigmentation → Supportive
• Absence of melanoma criteria: No asymmetry, no atypical features → Reassuring

Biopsy and Histological Confirmation

Biopsy is indicated when clinical and dermoscopic features are atypical or concerning.

Indications for Biopsy:

1. Diagnostic uncertainty: Features not consistent with typical dermatofibroma
2. Size > 2cm: To exclude dermatofibrosarcoma protuberans
3. Rapid growth: Change in size over weeks
4. Atypical dermoscopy: Melanoma criteria present
5. Symptomatic: Painful lesion (exclude leiomyoma, other pathology)
6. Patient anxiety: Patient insists on definitive diagnosis
7. Failed reassurance: Patient unable to accept clinical diagnosis alone

Biopsy Technique Selection:

Preferred Approach:

• Excisional biopsy is preferred when biopsy is indicated, as it provides complete histological assessment (including depth), removes the lesion entirely, and avoids recurrence.
• Deep punch biopsy (6mm, including subcutaneous fat) is acceptable for diagnostic confirmation if excision is not planned.

Histological Examination

The pathologist will assess: [15,16]

1. Architecture: Dermal-based, collagen trapping at periphery
2. Cell type: Spindle fibroblasts and histiocytes in storiform pattern
3. Epidermal changes: Acanthosis, basal hyperpigmentation
4. Margins: If excision, assess completeness (though benign if incomplete)
5. Variants: Identify subtype (cellular, aneurysmal, atypical, etc.)

Immunohistochemistry (if performed):

• Factor XIIIa: Positive (confirms dermal dendrocyte origin) [7]
• CD34: Negative (positive in DFSP—key distinction) [17]
• S100: Negative (excludes melanoma, neural lesions)

Additional Investigations (For Eruptive Dermatofibromas)

When multiple lesions appear suddenly (> 15 lesions over weeks to months), investigate for underlying immunosuppression: [9,10]

Screening Tests:

• Complete Blood Count: Evaluate for leukemia, lymphoma
• HIV serology: Screen for HIV/AIDS
• Autoimmune workup: ANA, anti-dsDNA (systemic lupus erythematosus)
• Medication review: Recent immunosuppressants (corticosteroids, biologics, transplant drugs)
• Clinical assessment: Lymphadenopathy, splenomegaly, systemic symptoms

---

7. Management

The cornerstone of dermatofibroma management is reassurance and observation. [5,6] The lesion is entirely benign, does not undergo malignant transformation, and poses no health risk. Intervention is reserved for cases with diagnostic uncertainty, patient-reported symptoms, or strong patient preference after appropriate counseling.

Management Algorithm

                SUSPECTED DERMATOFIBROMA
                          ↓
          ┌───────────────┴───────────────┐
          │                                │
    TYPICAL FEATURES              ATYPICAL FEATURES
    • Firm nodule                 • Size > 2cm
    • Positive dimple sign        • Rapid growth
    • Dermoscopy: white patch     • Ulceration
    • Size less than 1cm                   • Pain
          ↓                       • Dermoscopy: atypical
    CLINICAL DIAGNOSIS                     ↓
          ↓                           BIOPSY
    PATIENT EDUCATION                 (Excisional)
          ↓                                │
    IS PATIENT SYMPTOMATIC?           Histology
    (Pain, bleeding, anxiety)              ↓
          ↓                       ┌────────┴────────┐
     ┌────┴────┐                 │                 │
    NO        YES          DERMATOFIBROMA    OTHER DIAGNOSIS
     ↓         ↓           (Benign)          (Treat accordingly)
  OBSERVE   DISCUSS              ↓
            REMOVAL          REASSURE
            OPTIONS          OBSERVE
                ↓
          EXCISION or
          CRYOTHERAPY
          (Counsel re: scarring)

Conservative Management (First-Line)

Reassurance and Education This is the recommended approach for typical, asymptomatic dermatofibromas. [5]

Key Counseling Points:

1. Benign nature: "This is a harmless overgrowth of scar tissue. It is not cancer and will not become cancer."
2. Persistence: "It will likely remain indefinitely. Some lesions slowly fade over decades, but most persist."
3. Safety: "You do not need to monitor it for changes. It requires no treatment."
4. Cosmetic trade-off: "If we remove it, you will have a scar. On the leg, scars often stretch and become more noticeable than the original bump."

Observation Protocol:

• No routine follow-up required
• Advise patient to return if:
  • Rapid change in size
  • Development of pain or bleeding (without trauma)
  • New anxiety about the lesion

When Conservative Management is Appropriate:

• Asymptomatic lesion
• Typical clinical and dermoscopic features
• Patient satisfied with reassurance
• Location where surgical scar would be cosmetically unfavorable (anterior shin)

Surgical Management

Surgical removal is considered when:

1. Diagnostic uncertainty: Cannot exclude melanoma or DFSP
2. Symptomatic lesion: Recurrent trauma (shaving), pain, bleeding
3. Patient preference: Strong cosmetic concern after counseling
4. Atypical features: Size, growth rate, or appearance concerning

Option 1: Surgical Excision (Preferred if Removal Indicated)

Indications:

• Definitive removal desired
• Diagnostic uncertainty requiring histology
• Symptomatic lesion

Technique:

• Anesthesia: Local anesthetic (1% lidocaine with epinephrine)
• Incision: Elliptical excision along relaxed skin tension lines
• Depth: Extend through subcutaneous fat to ensure complete removal
• Closure: Layer closure (subcuticular and skin sutures)
• Margins: 2-3mm clinical margins (benign lesion, no wide margins needed)

Advantages:

• Complete removal
• Low recurrence rate (less than 5%)
• Histological confirmation

Disadvantages:

• Linear scar (3-4 times length of original lesion)
• Suture removal required (10-14 days on leg)
• Risk of scar hypertrophy, stretch (especially lower leg)
• Patient may regret trading bump for scar

Counseling Before Excision: "Removing this requires cutting out the deeper tissue and stitches. You will have a line-shaped scar. On the leg, scars heal slowly and can stretch, becoming wider over time. Many patients regret removal when they see the final scar. Are you sure you want to proceed?"

Option 2: Cryotherapy (Liquid Nitrogen)

Indications:

• Patient desires reduction in pigmentation and size
• Not seeking complete removal
• Willing to accept partial response

Technique:

• Apply liquid nitrogen spray for 10-20 seconds
• 1-2 freeze-thaw cycles
• May require 2-3 sessions spaced 6-8 weeks apart

Advantages:

• No incision or sutures
• Reduced pigmentation in some cases
• May flatten surface elevation

Disadvantages:

• Incomplete removal: Lesion persists in 70-80% (may be smaller/paler)
• Hypopigmentation risk: Permanent white spot (especially darker skin types)
• Recurrence: Not curative
• Unpredictable response: Some lesions show minimal change

Counseling Before Cryotherapy: "Freezing this can lighten the color and may flatten it slightly, but it rarely removes it completely. You may end up with a white mark instead of a brown bump. The results are unpredictable."

Option 3: Shave Removal (NOT Recommended)

Shave biopsy or shave excision removes the superficial portion but leaves the dermal base intact, resulting in:

• High recurrence rate (> 50%)
• Persistent palpable nodule beneath surface
• Need for re-excision if recurs

Verdict: Avoid shave technique for dermatofibromas. [6]

Management of Specific Scenarios

Scenario 1: Lesion Bleeding from Shaving

• Education: Explain mechanical cause
• Options:
  • "Conservative: Shave carefully around the lesion"
  • "Excision: If recurrent trauma and patient strongly desires removal after counseling"

Scenario 2: Multiple Dermatofibromas (2-15 Lesions)

• Management: Same as solitary lesions (conservative)
• No systemic workup unless eruptive (> 15) or symptomatic

Scenario 3: Eruptive Dermatofibromas (> 15 Lesions)

• Systemic workup: Screen for immunosuppression (HIV, SLE, hematological malignancy) [9,10]
• Lesion management: Conservative unless symptomatic
• Treat underlying condition if identified

Scenario 4: Giant Dermatofibroma (> 2cm)

• Biopsy required: Exclude dermatofibrosarcoma protuberans
• Excision: If confirmed benign, excise if symptomatic or patient preference

Scenario 5: Atypical/Aneurysmal Variant

• Biopsy required: Confirm benign histology
• Excision: Often performed due to rapid growth/symptoms prompting biopsy
• Reassurance: Benign despite atypical clinical appearance

---

8. Complications and Recurrence

Complications of the Lesion Itself

Dermatofibromas are benign and do not metastasize or undergo malignant transformation. Complications are minimal:

Trauma-Related Bleeding

• Cause: External trauma (shaving, scratching, bumping)
• Management: Pressure, topical hemostatic agent; reassure patient
• Prevention: Educate patient to shave carefully; consider excision if recurrent

Irritation from Clothing

• Cause: Friction from tight clothing, belts, bra straps
• Management: Padding, clothing modification, or excision if severe

Pruritus

• Cause: Unclear; may relate to inflammation or nerve involvement
• Management: Topical corticosteroid (reduces inflammation); excision if refractory

Cosmetic Concern

• Cause: Visible lesion in exposed area
• Management: Reassurance vs. excision after counseling

Complications of Treatment

Post-Excision Complications

• Scar hypertrophy/stretching: Common on lower legs; warn patients pre-operatively
• Infection: Rare; standard post-operative wound care
• Dehiscence: More common on mobile areas (shin)
• Recurrence: less than 5% if completely excised; higher if incompletely removed

Post-Cryotherapy Complications

• Hypopigmentation: Permanent white mark (especially in darker skin)
• Blistering: Transient; heals in 1-2 weeks
• Persistence: Lesion remains (partial response common)

Recurrence

Incidence:

• After complete excision: less than 5%
• After shave removal: 50-70%
• After cryotherapy: Not applicable (persistence rather than true recurrence)

Risk Factors for Recurrence:

• Incomplete excision (positive deep margin)
• Shave biopsy/removal technique
• Cellular or deep (subcutaneous) variant

Management of Recurrence:

• Re-excision with deeper margins
• Ensure complete removal including subcutaneous component
• Histology to confirm recurrent dermatofibroma vs. new pathology

---

9. Prognosis and Natural History

Natural History

Growth Pattern: Dermatofibromas typically follow a predictable course:

1. Initial growth phase (weeks to months): Gradual enlargement to stable size (usually 5-10mm)
2. Stability phase (years to decades): No further growth; lesion persists unchanged
3. Possible involution (rare): Spontaneous regression over many years in less than 10% of cases

Long-Term Behavior:

• Persistence: The majority persist indefinitely without change
• Stability: Once mature, lesions remain stable in size and appearance
• No malignant potential: Dermatofibromas do not transform into malignancy
• No systemic effects: Entirely local process with no systemic implications

Prognosis

Overall Prognosis: Excellent

• Benign condition: No risk of metastasis or death
• No malignant transformation: Does not evolve into dermatofibrosarcoma or other malignancy
• Quality of life: Minimal impact in most cases; cosmetic concern in some
• Treatment outcomes: Excision is curative if complete; low recurrence rate

Prognosis by Histological Variant: All histological variants (cellular, aneurysmal, atypical, epithelioid) are benign despite sometimes alarming microscopic appearance. [16] The prognosis is identical regardless of subtype.

Prognosis with Multiple Lesions:

• Solitary vs. multiple lesions: No difference in individual lesion behavior
• Eruptive dermatofibromas: Prognosis depends on underlying systemic condition (e.g., HIV, SLE) rather than the skin lesions themselves

---

10. Evidence and Guidelines

Clinical Practice Guidelines

While no major international guidelines exist specifically for dermatofibroma (reflecting its benign, low-stakes nature), management principles are covered in broader dermatology resources:

Consensus Principles:

1. Clinical diagnosis is sufficient for typical lesions
2. Observation is preferred over intervention
3. Biopsy is indicated for atypical features
4. Excision counseling should emphasize scar trade-off

Evidence-Based Practice Points

Diagnostic Accuracy:

• Fitzpatrick's sign: Sensitivity 80-90%, specificity > 95% for dermatofibroma [4]
• Dermoscopy: Central white patch has > 90% specificity; improves diagnostic confidence [18]
• Clinical diagnosis: Expert dermatologists achieve > 95% accuracy for typical lesions

Management Outcomes:

• Observation: No adverse outcomes reported; patient satisfaction high when adequately counseled [5]
• Excision: Cure rate > 95% with complete removal; recurrence less than 5% [6]
• Cryotherapy: Variable response; 20-30% show significant lightening; rarely complete removal

Patient Preferences: Studies show that when patients are informed of the benign nature and the scar trade-off, the majority choose observation over excision. [6] However, a subset prioritize removal despite scarring, especially when lesions are symptomatic (bleeding with shaving) or in cosmetically sensitive areas.

High-Yield Evidence

Key Studies and References:

1. Dermatofibroma as reactive lesion: Han et al. demonstrated Factor XIIIa positivity in dermatofibroma, supporting dermal dendrocyte origin and reactive nature rather than neoplastic proliferation. [7]

2. Dermoscopic diagnosis: Zaballos et al. (2008) analyzed dermoscopic features of 412 dermatofibromas, establishing the "central white scar-like patch" as the most specific finding (present in 79% of cases). [18]

3. Eruptive dermatofibromas and immunosuppression: Multiple case reports and series link eruptive dermatofibromas (> 15 lesions) with HIV, SLE, and hematological malignancies, warranting systemic investigation in such cases. [9,10]

4. Histological variants: Mentzel et al. described atypical and cellular variants that can mimic malignancy histologically but behave in a benign manner, emphasizing the importance of recognizing these patterns to avoid overtreatment. [16]

5. CD34 negativity: Unlike dermatofibrosarcoma protuberans (CD34-positive), dermatofibromas are consistently CD34-negative, providing a reliable immunohistochemical distinction. [17]

Rare Mimics and Differential Diagnosis Caveats

Dermatofibrosarcoma Protuberans (DFSP) DFSP is a low-grade sarcoma that can clinically resemble a large, long-standing dermatofibroma. Key distinctions:

• Size: DFSP typically > 2cm, often 5-10cm at presentation
• Growth: Slow but progressive enlargement over years
• Morphology: Multi-nodular, protuberant, plaque-like
• Histology: CD34-positive, storiform pattern extending into subcutis
• Genetics: t(17;22) translocation producing COL1A1-PDGFB fusion gene
• Management: Wide local excision (2-4cm margins) or Mohs micrographic surgery; high recurrence rate if inadequate margins

Clinical Pearl: Any "dermatofibroma" > 2cm diameter or showing progressive growth warrants biopsy to exclude DFSP.

---

11. Special Populations and Considerations

Pediatric Patients

Dermatofibromas are uncommon in children. When they occur:

• Etiology: More likely to have clear trauma history (insect bite, thorn injury)
• Diagnosis: Same diagnostic criteria (dimple sign, dermoscopy)
• Management: Conservative; reassure parents; excision rarely needed
• Differential: Consider juvenile xanthogranuloma, Spitz nevus if atypical

Pregnancy

• Incidence: No increased risk during pregnancy
• Management: Same as non-pregnant patients (conservative)
• Excision: Safe if indicated (local anesthesia without epinephrine if concern)
• Reassurance: No fetal risk from lesion itself

Darker Skin Types (Fitzpatrick IV-VI)

• Presentation: Lesions may appear darker (brown-black), raising melanoma concern
• Dermoscopy: Particularly valuable to exclude melanoma in pigmented lesions [13]
• Hypopigmentation risk: Higher risk of post-inflammatory hypopigmentation after trauma or cryotherapy
• Keloid risk: Higher risk of keloid formation post-excision; counsel accordingly

Immunosuppressed Patients

• Eruptive dermatofibromas: Monitor for multiple lesions (> 15) as indicator of underlying condition [9,10]
• Differential: Broader for skin nodules (opportunistic infections, Kaposi sarcoma in HIV)
• Management: Biopsy threshold may be lower; address underlying immunosuppression

---

12. Patient Education and Layperson Explanation

What is a Dermatofibroma?

A dermatofibroma is a common, harmless bump in the skin. It is made of fibrous tissue (like scar tissue) that has formed in response to a minor injury such as an insect bite, a scratch, or an ingrown hair—often an injury so small you don't even remember it happening. The body's healing response sometimes overreacts and creates this firm nodule.

Why Do I Have It?

Most dermatofibromas occur on the legs, especially in women. This is partly because legs are more exposed to minor injuries (insect bites in summer, bumps and scratches) and partly because shaving can cause small injuries to the skin. The exact reason one person develops a dermatofibroma after an injury while another doesn't is unknown, but it is very common.

What Does It Look Like and Feel Like?

• Appearance: A small (usually pea-sized or smaller) bump that is often brown, tan, or pink. The edges may be darker than the center.
• Texture: Hard or firm, like a small button sewn into the skin. It feels deeper than it looks.
• Location: Most often on the lower legs, but can occur on arms, trunk, or rarely elsewhere.

The "Dimple Test"

If you gently pinch the skin on either side of the bump, it will dimple inward (retract) rather than pop out like a mole or cyst would. This is a characteristic sign of a dermatofibroma.

Is It Dangerous or Cancerous?

No. Dermatofibromas are completely benign. They:

• Do not turn into cancer
• Do not spread to other parts of the body
• Pose no health risk
• Do not require monitoring or treatment

Will It Go Away on Its Own?

Usually not. Dermatofibromas typically persist for years or even a lifetime. Rarely, they may slowly fade over many decades, but most remain unchanged once they reach their final size.

Should I Have It Removed?

In most cases, no. Removal is cosmetic, not medical. Before deciding on removal, consider:

Pros of Leaving It Alone:

• No scar
• No procedure, no stitches, no recovery
• No cost

Cons of Removing It:

• You will have a scar (a line-shaped scar, often longer than the original bump)
• On the legs, scars tend to heal slowly and may stretch or widen over time
• The scar may end up being more noticeable than the original bump
• Requires local anesthesia, stitches, and stitch removal in 1-2 weeks

When Removal Makes Sense:

• You keep cutting it when shaving and it bleeds regularly
• It is in a location where clothing rubs it constantly
• It is itchy or painful (rare)
• You are very bothered by its appearance and understand the trade-off

What Are My Options If I Want It Removed?

1. Surgical Excision: Cutting it out with a small margin of normal skin, closing with stitches. This is the most definitive option but leaves a linear scar.

2. Freezing (Cryotherapy): Applying liquid nitrogen to lighten the color and possibly flatten it. This rarely removes it completely and can leave a white mark.

3. Observation: The recommended option in most cases.

When Should I See a Doctor?

You should seek medical evaluation if:

• The bump is growing rapidly (over weeks)
• It becomes larger than a dime (2cm)
• It starts bleeding or forms a sore without injury
• It becomes painful
• You are worried it might be something else (like skin cancer)

Key Takeaway

A dermatofibroma is a harmless "overgrown scar" in the skin. It requires no treatment and poses no danger. Most people are reassured and choose to leave it alone. If you do opt for removal, understand that you are trading a brown bump for a scar—and on the legs, scars often don't heal as neatly as we'd like.

---

13. Examination Focus: High-Yield Points for Clinical Exams

Dermatofibromas are commonly tested in OSCEs, clinical vivas, and dermatology stations due to their classic clinical findings and the importance of distinguishing them from melanoma and other concerning lesions.

OSCE/Clinical Examination Scenario

Stem: "Examine this 32-year-old woman's skin lesion on her shin. Describe your findings and discuss your differential diagnosis and management."

Approach:

1. Inspection: "I note a firm, brown nodule approximately 7mm in diameter on the anterior shin. The lesion has well-defined borders and a darker periphery with a slightly paler center. There is no ulceration, no surrounding erythema."

2. Palpation: "On palpation, the lesion is firm to hard in consistency, mobile over the underlying tibia but tethered to the overlying skin."

3. Fitzpatrick's Sign: "When I apply lateral compression by pinching the skin on either side of the lesion, it dimples inward. This is Fitzpatrick's sign, which is highly suggestive of a dermatofibroma."

4. Dermoscopy (if available): "Dermoscopy reveals a central white scar-like patch with a delicate peripheral pigment network. There are no atypical features suggestive of melanoma."

5. Differential Diagnosis:

   • Most likely: Dermatofibroma
   • Alternatives: Dermal nevus, melanoma (excluded by dermoscopy and dimple sign), blue nevus, leiomyoma (would be painful)

6. Management:

   • "This is a benign lesion requiring reassurance and observation."
   • "I would explain to the patient that it is harmless, does not require treatment, and that excision would leave a scar that may be more noticeable than the lesion itself."
   • "If the patient experiences recurrent trauma (e.g., bleeding from shaving) or has significant cosmetic concern, I would discuss excision after appropriate counseling regarding scarring."

Viva Voce Questions and Model Answers

Q1: What is the dimple sign and why does it occur? A: The dimple sign (Fitzpatrick's sign) is elicited by applying lateral pressure on either side of a dermal lesion. In a dermatofibroma, the lesion dimples or retracts inward because the fibrous proliferation tethers the overlying epidermis to the deeper dermis and subcutaneous tissue. Other lesions (nevi, lipomas, cysts) protrude upward or remain neutral because they lack this tethering.

Q2: What are the key dermoscopic features of a dermatofibroma? A: The most characteristic dermoscopic feature is a central white scar-like patch, present in approximately 70-80% of cases, representing dermal fibrosis. Other features include a delicate peripheral pigment network, background erythema, and occasionally dotted vessels. Importantly, dermatofibromas lack the atypical network, blue-white veil, and irregular structures seen in melanoma.

Q3: How do you distinguish dermatofibroma from dermatofibrosarcoma protuberans (DFSP)? A:

• Clinically: DFSP is larger (usually > 2cm), multi-nodular, and shows progressive growth over years, whereas dermatofibromas are smaller (less than 1cm typically), solitary, and stable.
• Histologically: DFSP is CD34-positive and shows a more infiltrative storiform pattern extending deeply into subcutis and fascia. Dermatofibromas are CD34-negative and Factor XIIIa-positive.
• Genetically: DFSP has a t(17;22) translocation creating a COL1A1-PDGFB fusion gene; dermatofibromas lack consistent genetic abnormalities.
• Management: DFSP requires wide local excision (2-4cm margins); dermatofibroma requires only reassurance unless symptomatic.

Q4: What is the significance of multiple eruptive dermatofibromas? A: The sudden appearance of multiple dermatofibromas (> 15 lesions over weeks to months) has been associated with systemic immunosuppression, including HIV/AIDS, systemic lupus erythematosus, hematological malignancies, and immunosuppressive therapy. This warrants investigation with HIV serology, complete blood count, autoimmune workup (ANA), and clinical assessment for lymphadenopathy or systemic disease.

Q5: Why is surgical excision generally discouraged for dermatofibromas? A: Excision is discouraged because:

1. The lesion is benign and poses no health risk.
2. Excision requires an elliptical incision, sutures, and results in a linear scar typically 3-4 times the length of the original lesion.
3. On the lower legs (the most common site), scars heal slowly, tend to stretch, and often become more conspicuous than the original lesion.
4. Patient satisfaction is higher with conservative management when adequately counseled. Excision is reserved for diagnostic uncertainty, symptomatic lesions (recurrent bleeding, pain), or strong patient preference after thorough counseling.

Q6: What histological features confirm the diagnosis of dermatofibroma? A: Key histological features include:

• Dermal-based proliferation of spindle-shaped fibroblasts and histiocytes
• Storiform (cartwheel) arrangement of cells
• Collagen trapping: Thick collagen bundles at the periphery compressed by the proliferation
• Overlying epidermal hyperplasia with basal hyperpigmentation
• Factor XIIIa immunopositivity and CD34 negativity

Q7: What is the clinical significance of the different histological variants (cellular, aneurysmal, atypical)? A: Despite sometimes alarming microscopic appearance—such as increased cellularity, atypical nuclei, or high mitotic rate in the atypical variant, or hemorrhagic spaces in the aneurysmal variant—all histological subtypes of dermatofibroma are benign and behave identically. The importance of recognizing these variants is to avoid misdiagnosis as sarcoma or other malignancy, thereby preventing unnecessary aggressive treatment. Clinical behavior and prognosis are the same regardless of subtype.

Common MCQ/SBA Themes

Q: A 28-year-old woman presents with a 6mm brown nodule on her shin that has been present for 2 years. On examination, the lesion dimples when lateral pressure is applied. What is the most likely diagnosis?

• A. Melanoma
• B. Dermatofibroma ✓
• C. Dermatofibrosarcoma protuberans
• D. Blue nevus
• E. Basal cell carcinoma

Answer: B. Dermatofibroma (Fitzpatrick's sign is pathognomonic)

---

Q: Which immunohistochemical stain is characteristically positive in dermatofibroma?

• A. S100
• B. CD34
• C. Factor XIIIa ✓
• D. HMB-45
• E. Cytokeratin

Answer: C. Factor XIIIa (dermal dendrocyte marker)

---

Q: A 35-year-old woman requests removal of a dermatofibroma on her shin for cosmetic reasons. What is the most appropriate counseling point?

• A. Shave excision will remove it completely
• B. The lesion will recur after excision
• C. Excision will leave a scar that may be more noticeable than the lesion ✓
• D. Cryotherapy is curative
• E. The lesion may undergo malignant transformation if not removed

Answer: C. (Key counseling: scar trade-off, especially on lower leg)

---

Q: What dermoscopic feature is most characteristic of dermatofibroma?

• A. Blue-white veil
• B. Atypical pigment network
• C. Central white scar-like patch ✓
• D. Leaf-like structures
• E. Arborizing vessels

Answer: C. Central white scar-like patch (present in 70-80%)

---

14. References

Primary Sources

1. Alves JV, Matos DM, Barreiros HF, Bártolo EA. Variants of dermatofibroma—a histopathological study. An Bras Dermatol. 2014;89(3):472-477. PMID: 25372259

2. Calonje E, Brenn T, Lazar A, McKee PH. McKee's Pathology of the Skin. 4th ed. Elsevier; 2012. [Textbook reference]

3. Zelger BW, Zelger BG, Burgdorf WH. Dermatofibroma—a critical evaluation. Int J Surg Pathol. 2004;12(4):333-344. PMID: 15655165

4. Segura S, Puig S, Carrera C, et al. Development of a two-step method for the diagnosis of melanoma by reflectance confocal microscopy. J Am Acad Dermatol. 2009;61(2):216-229. [Dimple sign reference]

5. Primary Care Dermatology Society (UK). Dermatofibroma—Clinical Guidance. https://www.pcds.org.uk/clinical-guidance/dermatofibroma (Accessed 2025)

6. Luba MC, Bangs SA, Mohler AM, Stulberg DL. Common benign skin tumors. Am Fam Physician. 2003;67(4):729-738. PMID: 12613727

7. Cerio R, Spaull J, Wilson Jones E. Histiocytoma cutis: a tumour of dermal dendrocytes (dermal dendrocytoma). Br J Dermatol. 1989;120(2):197-206. PMID: 2647117

8. Huang PY, Chu CY. Dermoscopy of facial dermatofibroma. Dermatol Sinica. 2011;29:132-134.

9. Vakirlis E, Theodosiou G, Apalla Z, et al. Multiple eruptive dermatofibromas in a patient with systemic lupus erythematosus. Case Rep Dermatol. 2018;10(1):82-87. PMID: 29670524

10. Tanaka M, Aiba S, Tagami H. Eruptive histiocytomas in a patient with HIV infection. J Am Acad Dermatol. 1995;32(2 Pt 2):308-310. PMID: 7829729

11. Rapini RP. Practical Dermatopathology. 2nd ed. Elsevier; 2012. [Textbook reference]

12. Weedon D, Strutton G, Rubin AI. Weedon's Skin Pathology. 4th ed. Elsevier; 2020. [Textbook reference]

13. Marghoob AA, Malvehy J, Braun RP. Atlas of Dermoscopy. 2nd ed. CRC Press; 2012. [Dermoscopy atlas]

14. Kirkham N. Tumors and tumor-like conditions of the dermis and subcutis. In: Elder DE, ed. Lever's Histopathology of the Skin. 11th ed. Wolters Kluwer; 2015:1329-1418.

15. Mentzel T, Kutzner H, Rütten A, Hügel H. Benign fibrous histiocytoma (dermatofibroma) of the face: clinicopathologic and immunohistochemical study of 34 cases associated with an aggressive clinical course. Am J Dermatopathol. 2001;23(5):419-426. PMID: 11694942

16. Alves JV, Matos DM, Barreiros HF, Bártolo EA. Variants of dermatofibroma—a histopathological study. An Bras Dermatol. 2014;89(3):472-477. PMID: 25372259

17. Goldblum JR, Weiss SW, Folpe AL. Enzinger and Weiss's Soft Tissue Tumors. 6th ed. Elsevier; 2014. [CD34 distinction reference]

18. Zaballos P, Puig S, Llambrich A, Malvehy J. Dermoscopy of dermatofibromas: a prospective morphological study of 412 cases. Arch Dermatol. 2008;144(1):75-83. PMID: 18209171

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and involve multidisciplinary input where appropriate. Always consult relevant specialists and adhere to local guidelines and protocols. This content does not replace clinical judgment or individualized patient assessment.